# US 2023/0192776 A1 · Rabbit haemorrhagic disease virus (rhdv) vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0192776 A1
- Document ID: US20230192776A1
- Status: Published application
- Kind: A1
- Application number: 17/881,816
- Filed: 2022-08-05
- Published: 2023-06-22
- Earliest claimed: 2021-08-05
- Assignees: VST LLC dba Medgene Labs
- Applicants: VST LLC dba Medgene Labs
- Inventors: Alan John Young
- Web page: https://patentgrep.com/patent/US20230192776A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55505: {Inorganic adjuvants}
- C12N 2770/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/16051: Methods of production or purification of viral material
- C12N 2770/16071: Demonstrated in vivo effect
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention describes immunogenic compositions containing immunogenic polypeptides of Rabbit Haemorrhagic Disease Virus (RHDV), including immunogenic compositions containing antigens other than RHDV antigens, including antigens that may be used in immunization against pathogens that cause diarrheal diseases. Methods of eliciting an immune response with the immunogenic compositions as disclosed and methods of treating a RHDV infection are also described.

## Claims

### Claim 1

A method for producing RHDV-derived immunogenic polypeptides and/or peptides, wherein optionally, said immunogenic polypeptides and/or peptides are mixed or co-expressed with one or more adjuvants.

### Claim 2 (depends on 1)

The method of claim 1, comprising culturing a host cell transformed with a nucleic acid under conditions which induce expression of said polypeptides and/or peptides.

### Claim 3 (depends on 2)

The method of claim 2, wherein the immunogenic polypeptides and/or peptides comprise a recombinant subunit vaccine, and wherein such expressed polypeptides and/or peptides are generated using baculovirus/insect cell methodology.

### Claim 4 (depends on 1)

The method of claim 1, wherein the polypeptides and/or peptides comprise the amino acid sequence as set forth in SEQ ID NO:2 or at least between 95% to about 99.9% identity to SEQ ID NO:2.

### Claim 5 (depends on 2)

The method of claim 2, wherein the nucleic acid encoding the RHDV derived immunogenic polypeptides and/or peptides is prepared by chemical synthesis.

### Claim 6 (depends on 5)

The method of claim 5, wherein the nucleic acid encoding the RHDV derived immunogenic polypeptides and/or peptides is generated using a primer-based amplification method.

### Claim 7 (depends on 6)

The method of claim 6, wherein the primer-based amplification method is PCR.

### Claim 8

An immunogenic composition comprising the polypeptide as set forth in SEQ ID NO:2 or at least between 95% to about 99.9% identity to SEQ ID NO:2.

### Claim 9 (depends on 8)

A method of eliciting an immunological response in a subject comprising administering a composition as set forth in claim 8.

### Claim 10 (depends on 9)

The method of claim 9, further comprising administering an adjuvant.

### Claim 11 (depends on 10)

The method of claim 10, wherein administering said immunogenic composition to said subject is via topical, parenteral or mucosal administration.

### Claim 12 (depends on 9)

The method of claim 9, wherein said administration is by multiple administrations.

### Claim 13 (depends on 12)

The method of claim 12, wherein a first immunogenic composition and a second immunogenic composition are the same.

### Claim 14 (depends on 12)

The method of claim 12, wherein a first immunogenic composition and the second immunogenic composition are different.

### Claim 15 (depends on 8)

A method for treating an infection by a RHDV comprising administering to a subject in need thereof a therapeutically effective amount of an immunogenic composition of claim 8.

### Claim 16

An isolated recombinant nucleic acid encoding a RHDV VP1 protein, wherein the encoding nucleic acid comprises i) a sequence as set forth in SEQ ID NO:1 or ii) nucleic acid having at least 80% sequence identity to the nucleic acid sequences as set forth in SEQ ID NO:1, or combinations thereof.

### Claim 17 (depends on 16)

The isolated recombinant nucleic acid of claim 16, wherein the encoding nucleic acid is recombined with a vector.

### Claim 18 (depends on 17)

The isolated recombinant nucleic acid of claim 17, wherein the vector is a baculovirus vector.

### Claim 19 (depends on 18)

The isolated recombinant nucleic acid of claim 18, wherein the vector is contained in a host cell.

### Claim 20 (depends on 19)

The isolated recombinant nucleic acid of claim 19, wherein the host cell is an insect cell.
